Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

1

Inhibition of CD30 on CD19 CAR T cells enhances their efficacy against B-cell leukemia and lymphoma by preventing T-cell activation decline.
2

The bispecific CD30/CD19 CAR T cells outperformed canonical CD19 CAR T cells in eliminating CD30-CD19+ leukemia cells in vitro.
3

Blocking the CD30–CD30L interaction reduces TRAF2 levels and alters T-cell signaling, enhancing cytotoxic functions of CAR T cells.
4

The optimal synaptic gap formation for CAR T cells occurs with the scFv order CD30/CD19, improving T-cell activation and functionality.
5

This study presents a novel strategy to augment CD19 CAR T-cell efficacy by targeting the T-cell's own regulatory mechanisms.

Frontiers In Immunology

by Tim Schlierkamp-Voosen, Markus Barden, Helena Janning, Marcell Kaljanac, Dennis Christoph Harrer, Celine Dreger, Kathrin Hammon, Moritz Ertelt, Clara T. Schoeder, Hólmfridur Rósa Halldórsdóttir, Carlos Rodriguez-Pardo, Sine Reker Hadrup, Simone Thomas, Hinrich Abken
April 30, 2026

1